This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Drug Therapy, Other  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael H. Alderman, MD

JAMA. 2003;290:2859-2861.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A decade ago, practitioners who prescribed antihypertensive therapy, and their patients, were transfixed by a passionate and sometimes unseemly public debate over whether dihydropyridine calcium antagonists (not the verapamil type) were safe.¹ Aware that the available scientific data were insufficient, contending parties, although agreeing on little else, were all willing to submit their positions to the test of rigorous clinical trials. The missing data now have been provided.² Disappointingly, while some concerns about calcium antagonists have been laid to rest, their role in antihypertensive therapy remains controversial. Disputants who had thrived on extrapolation from observational data now disagree about how to interpret and apply the abundance of clinical trial data.

The INVEST trial,³ reported in this issue of THE JOURNAL, is the latest addition to a growing database. This trial was designed to "compare mortality and morbidity outcomes in patients with hypertension and CAD [coronary artery . . . [Full Text of this Article]

Author Affiliation: Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial
Carl J. Pepine, Eileen M. Handberg, Rhonda M. Cooper-DeHoff, Ronald G. Marks, Peter Kowey, Franz H. Messerli, Giuseppe Mancia, José L. Cangiano, David Garcia-Barreto, Matyas Keltai, Serap Erdine, Heather A. Bristol, H. Robert Kolb, George L. Bakris, Jerome D. Cohen, and William W. Parmley
JAMA. 2003;290(21):2805-2816.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Calcium Antagonists vs. Beta-Blockers for Hypertensive CAD Patients
Journal Watch Cardiology 2004;2004:6-6.
FULL TEXT  

A Large Hypertension Trial, Focused on CAD Patients
JWatch General 2003;2003:1-1.
FULL TEXT  

Cardiovascular News
SoRelle
Circulation 2003;108 :e9077-e9078.
FULL TEXT